Modeling how drug combinations affect cancer cell behavior
Mechanistic Pharmacodynamic Modeling for Drug Combination Responses
['FUNDING_OTHER'] · CLEMSON UNIVERSITY · NIH-11053466
This study is exploring new ways to predict how different combinations of cancer drugs will work on cancer cells, helping doctors find the best treatments for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEMSON UNIVERSITY (nih funded) |
| Locations | 1 site (CLEMSON, UNITED STATES) |
| Trial ID | NIH-11053466 on ClinicalTrials.gov |
What this research studies
This research focuses on developing advanced models to predict how different drug combinations will affect cancer cells. By integrating concepts from pharmacology, physics, and engineering, the team aims to simulate the responses of cancer cells to various drug combinations, which is often difficult to test in real-life scenarios. The approach involves analyzing single-cell behavior, including how they grow and die when exposed to these combinations. This innovative methodology seeks to enhance drug development and precision medicine by providing more accurate predictions of treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer who may benefit from personalized drug combination therapies.
Not a fit: Patients who are not undergoing treatment for cancer or those with conditions unrelated to drug combination therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by optimizing drug combinations tailored to individual patient needs.
How similar studies have performed: Other research has shown promise in using mechanistic modeling approaches for drug responses, indicating potential for success in this novel application.
Where this research is happening
CLEMSON, UNITED STATES
- CLEMSON UNIVERSITY — CLEMSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BIRTWISTLE, MARC R. — CLEMSON UNIVERSITY
- Study coordinator: BIRTWISTLE, MARC R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer cell line